Breakthrough PTSD treatment achieves 68% remission rate in clinical trial

AI Summary

A newly FDA-cleared PTSD treatment combines personalized brain mapping with magnetic stimulation, and a clinical trial reported a 52% symptom reduction and 68% remission rate. Researchers say this targeted approach could expand precision treatment for PTSD and other mental health conditions.

A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.